Pipeline Review: Large Potential Overactive Bladder Population Beckons
Fourteen drugs are in clinical development for overactive bladder, most of which are early-to-mid stage and oral.
You may also be interested in...
ParaPatch developed patch to commercialize a home remedy and was chosen from a record number of submissions in contest. It will receive $10,000 and opportunity to partner with P&G Ventures to continue development.
Roivant subsidiary thinks EMPOWUR data would position the drug as best-in-class in overactive bladder, but investors responded to the data with a clear thumbs-down.
Anthos premiers with $250m from Blackstone and cardiovascular disease assets and expertise from Novartis, while Maze brings in $191m for drugs that target gene modifiers. In public company financings, Sage raises $575m ahead of Zulresso approval decision.